ArticleOncology2026
Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer.
Article in Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiotherapy is a cornerstone of laryngeal cancer treatment. MRE11, a key component of the MRN complex, and the ATM protein are important elements of DNA repair. This study examines the impact of MRE11 and ATM on treatment outcomes in laryngeal cancer patients treated at Bulovka University Hospital in Prague.
methodsThis retrospective study included 108 patients with laryngeal cancer treated with radiotherapy. Immunohistochemical (IHC) analysis of pretreatment biopsy samples was performed to evaluate MRE11 and ATM expression and statistically estimate the impact on treatment outcomes.
resultsStatistically significant differences were found in subgroups of patients according to the IHC positivity of at least one of these two proteins. A statistically significant association was confirmed between IHC positivity for MRE11 or ATM protein (at least one of them) and better overall survival (OS; p < 0.001). IHC negativity for both proteins was found only in patients in clinical stage IV (p < 0.001) with the shortest OS confirmed in this subgroup of patients.
conclusionHigh IHC expression of MRE11 and ATM proteins was associated with earlier clinical stages and better treatment outcomes in laryngeal carcinoma, particularly when both proteins were elevated. The results point to the potential of MRE11 and ATM as predictors of treatment response, but more extensive molecular and clinical research would be needed to gain a more detailed insight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.